Molecule Details
| InChIKey | HUJXGQILHAUCCV-MOROJQBDSA-N |
|---|---|
| Compound Name | IB-Meca |
| Canonical SMILES | CNC(=O)[C@H]1O[C@@H](n2cnc3c(NCc4cccc(I)c4)ncnc32)[C@H](O)[C@@H]1O |
| Clinical Status | Data-mined Candidate |
| Targets (Human+Pathogen) | 3 |
| Pfam Stratification | Homologous |
| Avg pChEMBL | 7.75 |
| Source | ChEMBL;BindingDB |
2D Structure
Activity Profile
DrugBank Annotations
| DrugBank ID | DB05511 |
|---|---|
| Drug Name | Piclidenoson |
| CAS Number | 152918-18-8 |
| Groups | investigational |
| ATC Codes | nan |
| Description | CF 101 (known generically as IB-MECA) is an anti-inflammatory drug for rheumatoid arthritis patients. Its novel mechanism of action relies on antagonism of adenoside A3 receptors. CF101 is supplied as an oral drug and has an excellent safety profile. It is also being considered for the treatment of ... |
Categories: Heterocyclic Compounds, Fused-Ring Nucleic Acids, Nucleotides, and Nucleosides Nucleosides Purine Nucleosides Purines Ribonucleosides
Cross-references: BindingDB: 50118812 ChEBI: 73286 CHEMBL119709 ChemSpider: 110259 PDB: Q8L PubChem:123683 PubChem:175427023 ZINC: ZINC000003811810
Target Activities (3)
DrugBank Target Actions (1)
| Target | Gene | Target Name | Action | Type |
|---|---|---|---|---|
| P0DMS8 | ADORA3 | Adenosine receptor A3 | agonist | targets |